Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Market cap
$4.3B
87M shares
52-week range
$20.13 – $51.78
90% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NASDAQ
CS
P/S (TTM)
19.7
HeartFlow Inc is a commercial-stage medical technology company that provides software and artificial intelligence (AI) designed to deliver a non-invasive solution for diagnosing and managing coronary artery disease. The company operates and manages its business as a single reportable operating segment: non-invasive coronary artery disease detection solutions. Geographically, it operates in the United States and the rest of Europe, deriving the majority of its revenue from the United States. The company has developed three software products: Heartflow Roadmap Analysis, Heartflow FFRCT Analysis, and Heartflow Plaque Analysis.
www.heartflow.comNo one on the platform currently holds HTFL.
No tracked institution reports a position in HTFL as of their last filing.
No one on the platform has traded HTFL yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| Rev. Growth % | 39.9% | |||||
| Profit Margin % | -66.3% | |||||
| Free Cash Flow Margin % | -33.5% | |||||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $249M | +43.5% | $-0.41 | $-0.45–$-0.38 | — | 6 |
| 2027 | $309M | +24.1% | $-0.26 | $-0.47–$-0.15 | — | 6 |
| 2028 | $371M | +20.1% | $0.07 | $-0.14–$0.43 | 696.6× | 3 |
| 2029 | $444M | +19.6% | $0.35 | $0.34–$0.36 | 137.1× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 4 of the last 6 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-13 | $-0.13 | $-0.07 | +47.6% |
| 2026-05-14 | $-0.19 | $-0.16 | +14.7% |
| 2026-03-18 | $-0.19 | $-0.12 | +36.0% |
| 2025-11-12 | $-0.20 | $-0.27 | -35.0% |
| 2025-09-19 | $-0.21 | $-0.06 | +71.8% |
| 2025-07-17 | $-0.21 | $-0.46 | -116.0% |
| $4.4B |
| — |
| PRGOPerrigo Company plc | $13.65 | -0.07% | $1.9B | — |
| PRVAPrivia Health Group, Inc. | $20.88 | +2.25% | $2.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Heartflow, Inc. ( $HTFL ) SpicyTrade - Daily Stock Analysis https://youtu.be/73oLqgkMDA8?si=yhgXmEcpS_ch_iWB
View on StockTwits ↗
$HTFL this is one of the best stocks on the market. I should have went long instead of short !
View on StockTwits ↗
$HTFL some magical algo keeps it at 50, not more, not less
View on StockTwits ↗$HTFL I think some institution has a grip on this. They are playing the stock back and forth , and profiting each direction
View on StockTwits ↗
$HTFL Sold all 50,000 shares and ran away like a scared dog! 😂 I wanted to hold longer, but I have a feeling the institutions are about to dump their shares. I’m happy I got out first. Good luck, everyone! 🐕💨
View on StockTwits ↗$HTFL if this ever sees low $30’s again, I’ll be buying a pile of shares
View on StockTwits ↗
$HTFL this stock has held gains better than anything I’ve seen
View on StockTwits ↗
$HTFL Technical mean reversion setup for those interested... Parabolic vertical expansions disconnected from structural baselines rarely resolve sideways. HTFL is flashing clear exhaustion signals after printing a clean double-top rejection against R-1 ($51.18) and closing down at ~$47.76 (-2.37%). Momentum roll: RSI (14) has breached back under 70 to 67.95, while Stochastics flashed a bearish cross out of overbought territory (66.65 / 70.98). Dynamic gap: The tape sits severely dislocated from dynamic moving averages (50 SMA at $34.16 / 200 SMA at $30.03), leaving plenty of air below. Key levels I'm watching... Invalidation (R-1): $51.18 (Daily close above invalidates the short thesis). Target 1 (S-1): $40.71 (Q4 2025 prior breakout shelf)... will look to take some off here... tactical profits/de-risking. Target 2 (S-2): $36.53 (Secondary structural baseline above the 50 SMA). Full exit. Puts initiated off the double top remain in control as long as R-1 holds. Managing risk into S-1. Always DYOR. NFA.
View on StockTwits ↗
Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.